Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat

Submental Fat Clinical Trial

Official title:

A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05195112
• Other study ID #: MT11-KR19SMF309
• Status: Completed
• Phase: Phase 3
• Start date: December 24, 2021
• Est. completion date: February 18, 2023

Study information

• Verified date: February 2023
• Source: Medy-Tox
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the Efficacy and Safety of MT921 in Subjects with Moderate to Severe Submental fat compared with Placebo.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 240
• Est. completion date: February 18, 2023
• Est. primary completion date: February 18, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Adults 19~65 years of age

2. CA-SMFRS and PA-SMFRS score of 2 or 3

3. Satisfaction level is 3points or less

4. Voluntarily provide informed consent

Exclusion Criteria:

1. Following history that can affect the efficacy and safety evaluation in the chin or neck area as judged by the investigator

• Scars or skin lesion on the study treatment region
• Liposuction or lipolytic material treatment to decrease submental fat
• Permanent filler, synthetic implantation and autologous fat grafting
• Within 1 year of screening visit, semi-permanent filler (Calcium Hydroxyapatite, collagen-stimulator, etc.), radio-frequency treatment, HIFU, thread, laser procedure and chemical peeling procedure over medium-depth
• Within 6 months of screening visit, temporary filler (Hyaluronic acid, etc.) procedure on the chin or neck, injection of botulinum toxin, radio-frequency treatment, HIFU, thread, laser procedure and chemical peeling procedure over medium-depth

2. BMI over 35.0 kg/m^2

3. Submandibular enlargement due to causes other than localized subcutaneous fat (hyperthyroidism, cervical lymphadenopathy, etc.)

4. Current or past dysphagia

5. Judged difficult to measure submandibular fat due to sagging skin on the chin and neck or wide platysmal bands on the neck

6. Bleeding or taking anticoagulant drugs (except for patients taking anticoagulant drugs, those who can discontinue administration from 3 days before injection to 24 hours after injection of the IP)

7. Skin disease or would infection on the study treatment region

8. Hypersensitivity to Lidocaine, Benzocaine, Procaine or the IP

9. Pregnancy or breast feeding or female of child-bearing potential who has not agreed to use of medically acceptable contraception during the study period

• All women of childbearing age have negative pregnancy test results can be enrolled in parallel with surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or menopause (amenorrhea for more than 12 months).
• Medically acceptable contraception: Intrauterine device, Intrauterine system, vasectomy, tubal ligation, condom, Cervical cap, Contraceptive diaphragm, contraceptive sponges, spermicide, oral contraceptive pill and etc.

10. Experience of other clinical trials within 30 days before screening

11. Any other clinically meaningful conditions that are considered ineligible for the study in the medical judgement of principal investigator or sub-investigator

Related Conditions & MeSH terms

• Submental Fat

Intervention

Drug:
• MT921
Active ingredient
• Placebo
Normal Saline

Locations

Country	Name	City	State
Korea, Republic of	Inha University Hospital	Incheon

Sponsors (1)

Lead Sponsor	Collaborator
Medy-Tox

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Caliper	Percentage of change in submental fat thickness as measured by Caliper	4 and 12 weeks
Primary	Proportion of subjects whose CA-SMFRS (Clinician-Assessed Submental Fat Rating Scale) score changed	Proportion of subjects whose CA-SMFRS decreased 1, 2 points or more compared the 12 weeks after the last administration day to before administration of the IP, Minimum value: 0 (best outcome) / Maximum value: 4 (worst outcome)	12 weeks
Primary	Proportion of subjects whose PA-SMFIS (Patient Assessed-Submental Fat Impact Scale) score changed	Proportion of subjects whose PA-MFRS decreased 1, 2 points or more compared the 12 weeks after the last administration day to before administration of the IP , Minimum value: 0 (worst outcome) / Maximum value: 10 (best outcome)	12 weeks
Secondary	Proportion of subjects whose CA-SMFRS (Clinician-Assessed Submental Fat Rating Scale) score changed	Proportion of subjects whose CA-SMFRS decreased 1, 2 points or more compared the 4 weeks after the last administration day to before administration of the IP, Minimum value: 0 (best outcome) / Maximum value: 4 (worst outcome)	4 weeks
Secondary	Proportion of subjects whose PA-SMFIS (Patient Assessed-Submental Fat Impact Scale) score changed	Proportion of subjects whose PA-MFRS decreased 1, 2 points or more compared the 4 weeks after the last administration day to before administration of the IP , Minimum value: 0 (worst outcome) / Maximum value: 10 (best outcome)	4 weeks
Secondary	PA-SMFIS (Patient Assessed-Submental Fat Impact Scale)	Change PA-SMFIS (Patient Assessed-Submental Fat Impact Scale) score compared 4 to 12 weeks after the last administration of the IP, Minimum value: 0 (worst outcome) / Maximum value: 10 (best outcome)	4 and 12 weeks
Secondary	Measuring submental fat volume by MRI (magnetic resonance imaging)	Confirmation the volume of submental fat compared the 12 weeks after the last administration to before administration of the IP measured by MRI (Number of Participants: approximately 120)	12 weeks
Secondary	Satisfaction Evaluation by the subject	A score of 5 (slightly satisfied) or higher in the subject satisfaction evaluation at 4 and 12 weeks after the last administration to before administration of the IP	4 and 12 weeks